SLC5A2 and chronic kidney disease: Is the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors associated with reduced risk of anemia in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) stages 1 to 3?